Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

ksj pharmatech - glucosamine sulfate, quantity: 3 mg/g; shark sodium chondroitin sulfate, quantity: 7.2 mg/g; camphor, quantity: 32 mg/g - cream - excipient ingredients: acetylated lanolin; acrylates/c10-30 alkyl acrylate crosspolymer; carbomer u-10; alkyl (c12-15) benzoate; diazolidinyl urea; dimeticone 1000; dimeticonol stearate; disodium edetate; glycerol; glyceryl monostearate; hydroxylated lanolin; hypromellose; aloe vera; iodopropynyl butylcarbamate; methyl gluceth-20; methyl glucose sesquistearate; peppermint oil; polysorbate 20; potassium hydroxide; dl-alpha-tocopheryl acetate; shark cartilage; panthenol; purified water - decrease/reduce/relieve mild joint aches and pains ; decrease/reduce/relieve symptoms of mild arthritis/mild osteoarthritis ; helps maintain/supports healthy joint cartilage growth/development/production ; helps maintain/support joint cartilage health ; helps enhance/promote healthy joint function ; decrease/reduce/relieve mild joint inflammation/swelling ; maintain/support joint mobility/flexibility ; helps enhance/improve/promote joint mobility ; maintain/support muscle health ; maintain/support muscle function ; decrease/reduce/relieve muscle pain/ache/soreness ; decrease/reduce/relieve muscle tension/stiffness ; decrease/reduce/relieve muscle tiredness

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

hughes australia pty ltd - phenylbenzimidazole sulfonic acid, quantity: 40 mg/g; ethylhexyl triazone, quantity: 20 mg/g; diethylamino hydroxybenzoyl hexyl benzoate, quantity: 55 mg/g; titanium dioxide, quantity: 20 mg/g - lotion - excipient ingredients: purified water; phenoxyethanol; camellia sinensis; sodium hydroxide; propanediol; hydroxyacetophenone; alkyl (c12-15) benzoate; dibutyl adipate; dicaprylyl carbonate; pvp/eicosene copolymer; rice bran wax; octyldodecanol; octyldodecyl xyloside; peg-30 dipolyhydroxystearate; hydrated silica; dimeticone 5; polyhydroxystearic acid; dimeticonol; isocetyl alcohol; ceramide 3; cetyl alcohol; aloe vera; sodium hyaluronate - may assist in preventing some skin cancers (sunscreen) ; may reduce the risk of some skin cancers (sunscreen) ; spf 50 plus broad spectrum very high protection sunscreen ; can aid in the prevention of premature skin ageing (sunscreen) ; can aid in the prevention of solar keratosis (sunscreen) ; can aid in the prevention of sunspots (sunscreen)

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

hughes australia pty ltd - phenylbenzimidazole sulfonic acid, quantity: 40 mg/g; ethylhexyl triazone, quantity: 20 mg/g; diethylamino hydroxybenzoyl hexyl benzoate, quantity: 55 mg/g; titanium dioxide, quantity: 20 mg/g - lotion - excipient ingredients: purified water; phenoxyethanol; camellia sinensis; sodium hydroxide; propanediol; hydroxyacetophenone; alkyl (c12-15) benzoate; dibutyl adipate; dicaprylyl carbonate; pvp/eicosene copolymer; rice bran wax; octyldodecanol; octyldodecyl xyloside; peg-30 dipolyhydroxystearate; hydrated silica; dimeticone 5; polyhydroxystearic acid; kaolin; iron oxide red; iron oxide black; iron oxide yellow; dimeticonol; isocetyl alcohol; ceramide 3; cetyl alcohol; aloe vera; sodium hyaluronate - may assist in preventing some skin cancers (sunscreen) ; may reduce the risk of some skin cancers (sunscreen) ; spf 50 plus broad spectrum very high protection sunscreen ; can aid in the prevention of premature skin ageing (sunscreen) ; can aid in the prevention of solar keratosis (sunscreen) ; can aid in the prevention of sunspots (sunscreen)

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

hughes australia pty ltd - phenylbenzimidazole sulfonic acid, quantity: 40 mg/g; ethylhexyl triazone, quantity: 20 mg/g; diethylamino hydroxybenzoyl hexyl benzoate, quantity: 55 mg/g; titanium dioxide, quantity: 20 mg/g - lotion - excipient ingredients: purified water; phenoxyethanol; camellia sinensis; sodium hydroxide; propanediol; hydroxyacetophenone; alkyl (c12-15) benzoate; dibutyl adipate; dicaprylyl carbonate; pvp/eicosene copolymer; rice bran wax; octyldodecanol; octyldodecyl xyloside; peg-30 dipolyhydroxystearate; hydrated silica; dimeticone 5; polyhydroxystearic acid; kaolin; iron oxide red; iron oxide black; iron oxide yellow; dimeticonol; isocetyl alcohol; ceramide 3; cetyl alcohol; aloe vera; sodium hyaluronate - may assist in preventing some skin cancers (sunscreen) ; may reduce the risk of some skin cancers (sunscreen) ; spf 50 plus broad spectrum very high protection sunscreen ; can aid in the prevention of premature skin ageing (sunscreen) ; can aid in the prevention of solar keratosis (sunscreen) ; can aid in the prevention of sunspots (sunscreen)

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - atorvastatin calcium trihydrate, quantity: 43.38 mg (equivalent: atorvastatin, qty 40 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; magnesium stearate; polysorbate 80; croscarmellose sodium; calcium carbonate; hyprolose; lactose monohydrate; titanium dioxide; macrogol 8000; hypromellose; purified talc; purified water; sodium chloride; dimeticone 100; benzoic acid; sorbic acid; methylcellulose; polysorbate 65; glyceryl distearate; silicon dioxide; dimeticonol; peg-4 stearate - as an adjunct to diet for the treatment of patients with hypercholesterolaemia. prior to initiating therapy with atorvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy and alcoholism) should be identified and treated.,indicated in hypertensive patients with multiple risk factors for coronary heart disease (chd), which may include diabetes, history of stroke or other cerebrovascular disease, peripheral vascular disease or existing asymptomatic chd (see clinical trials, prevention of cardiovascular disease) to reduce the risk of non-fatal myocardial infarction and non-fatal stroke. these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - atorvastatin calcium trihydrate, quantity: 21.69 mg (equivalent: atorvastatin, qty 20 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; croscarmellose sodium; polysorbate 80; hyprolose; magnesium stearate; calcium carbonate; microcrystalline cellulose; purified water; sodium chloride; dimeticone 100; benzoic acid; sorbic acid; methylcellulose; polysorbate 65; glyceryl distearate; silicon dioxide; dimeticonol; peg-4 stearate; titanium dioxide; macrogol 8000; hypromellose; purified talc - as an adjunct to diet for the treatment of patients with hypercholesterolaemia. prior to initiating therapy with atorvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy and alcoholism) should be identified and treated.,indicated in hypertensive patients with multiple risk factors for coronary heart disease (chd), which may include diabetes, history of stroke or other cerebrovascular disease, peripheral vascular disease or existing asymptomatic chd (see clinical trials, prevention of cardiovascular disease) to reduce the risk of non-fatal myocardial infarction and non-fatal stroke. these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - atorvastatin calcium trihydrate, quantity: 10.845 mg (equivalent: atorvastatin, qty 10 mg) - tablet, film coated - excipient ingredients: hyprolose; polysorbate 80; croscarmellose sodium; calcium carbonate; microcrystalline cellulose; magnesium stearate; lactose monohydrate; purified water; sodium chloride; dimeticone 100; benzoic acid; sorbic acid; methylcellulose; polysorbate 65; glyceryl distearate; silicon dioxide; dimeticonol; peg-4 stearate; titanium dioxide; macrogol 8000; hypromellose; purified talc - as an adjunct to diet for the treatment of patients with hypercholesterolaemia. prior to initiating therapy with atorvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy and alcoholism) should be identified and treated.,indicated in hypertensive patients with multiple risk factors for coronary heart disease (chd), which may include diabetes, history of stroke or other cerebrovascular disease, peripheral vascular disease or existing asymptomatic chd (see clinical trials, prevention of cardiovascular disease) to reduce the risk of non-fatal myocardial infarction and non-fatal stroke. these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - atorvastatin calcium trihydrate, quantity: 10.845 mg (equivalent: atorvastatin, qty 10 mg) - tablet, film coated - excipient ingredients: magnesium stearate; calcium carbonate; lactose monohydrate; croscarmellose sodium; hyprolose; microcrystalline cellulose; polysorbate 80; titanium dioxide; macrogol 8000; hypromellose; purified talc; purified water; sodium chloride; dimeticone 100; benzoic acid; sorbic acid; methylcellulose; polysorbate 65; glyceryl distearate; silicon dioxide; dimeticonol; peg-4 stearate - as an adjunct to diet for the treatment of patients with hypercholesterolaemia. prior to initiating therapy with atorvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy and alcoholism) should be identified and treated.,indicated in hypertensive patients with multiple risk factors for coronary heart disease (chd), which may include diabetes, history of stroke or other cerebrovascular disease, peripheral vascular disease or existing asymptomatic chd (see clinical trials, prevention of cardiovascular disease) to reduce the risk of non-fatal myocardial infarction and non-fatal stroke. these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - atorvastatin calcium trihydrate, quantity: 10.845 mg (equivalent: atorvastatin, qty 10 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; hyprolose; lactose monohydrate; polysorbate 80; calcium carbonate; magnesium stearate; purified water; sodium chloride; dimeticone 100; benzoic acid; sorbic acid; methylcellulose; polysorbate 65; glyceryl distearate; silicon dioxide; dimeticonol; peg-4 stearate; titanium dioxide; macrogol 8000; hypromellose; purified talc - as an adjunct to diet for the treatment of patients with hypercholesterolaemia. prior to initiating therapy with atorvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy and alcoholism) should be identified and treated.,indicated in hypertensive patients with multiple risk factors for coronary heart disease (chd), which may include diabetes, history of stroke or other cerebrovascular disease, peripheral vascular disease or existing asymptomatic chd (see clinical trials, prevention of cardiovascular disease) to reduce the risk of non-fatal myocardial infarction and non-fatal stroke. these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - atorvastatin calcium trihydrate, quantity: 43.38 mg (equivalent: atorvastatin, qty 40 mg) - tablet, film coated - excipient ingredients: polysorbate 80; lactose monohydrate; hyprolose; croscarmellose sodium; magnesium stearate; calcium carbonate; microcrystalline cellulose; purified water; sodium chloride; dimeticone 100; benzoic acid; sorbic acid; methylcellulose; polysorbate 65; glyceryl distearate; silicon dioxide; dimeticonol; peg-4 stearate; titanium dioxide; macrogol 8000; hypromellose; purified talc - as an adjunct to diet for the treatment of patients with hypercholesterolaemia. prior to initiating therapy with atorvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy and alcoholism) should be identified and treated.,indicated in hypertensive patients with multiple risk factors for coronary heart disease (chd), which may include diabetes, history of stroke or other cerebrovascular disease, peripheral vascular disease or existing asymptomatic chd (see clinical trials, prevention of cardiovascular disease) to reduce the risk of non-fatal myocardial infarction and non-fatal stroke. these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.